Interestingly, PDE9 inhibitors have been investigated as modulators of the nitric oxide/guanylate cyclase/PKG signalling pathway as a therapeutic strategy 27, 28 and are currently under evaluation in clinical trials as cognitive enhancers for AD. The gene discussed is PRKG1; the disease is Alzheimer disease.